Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
The present disclosure relates to the use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease. In particular the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the THCV used is in the form of a botanically derived purified THCV. Alternatively, a synthetically produced THCV is used.
1. A method of treating dyskinesia associated with Parkinson's disease comprising administering a therapeutically effective amount of Tetrahydrocannabivarin (THCV).
2. The method of claim 1 , wherein the therapeutically effective amount of THCV is between 0.1 and 1000 mg/kg day.
3. The method of claim 1 , wherein the THCV is botanically derived highly purified THCV.
4. The method of claim 1 , wherein the THCV is synthetic THCV.